Mechlorethamine (Mustargen)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.[1][2]
Route: IV, intracavitary
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 3/15/1949: Initial FDA approval (This is the first chemotherapy agent ever approved)
  • 2/9/2004 (only label available at Drugs @ FDA):
  1. "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
  2. "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."

Also known as

  • Generic name: nitrogen mustard
  • Brand names: Chlormethine, Mustargen, Mustine

References

  1. 1.0 1.1 Mechlorethamine (Mustargen) package insert
  2. Mechlorethamine (Mustargen) package insert (locally hosted backup)
  3. Mechlorethamine (Mustargen) patient drug information (Chemocare)
  4. Mechlorethamine (Mustargen) patient drug information (UpToDate)